Biomarker & Intervention Discovery
Inflammatory Myopathies (Dermatomyositis / PM / IBM)
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
Spontaneous remissionSpontaneous remission in ~10-15% over 2 years without treatment; IBM (inclusion body myositis) is slowly progressive…
Best-intervention remissionHigh-dose corticosteroids + IVIG + steroid-sparing agent (methotrexate/azathioprine): clinical remission in 40-60% of…
Gap sizeLarge for IBM (no effective treatment); moderate for DM/PM
Primary barrierbiological (IBM) + practice (DM/PM undertreated)
Full remission profile →
Remission & chronicity
Spontaneous remission
Spontaneous remission in ~10-15% over 2 years without treatment; IBM (inclusion body myositis) is slowly progressive with no effective treatment; death from interstitial lung disease in dermatomyositis in 5-10%
Best-intervention remission
High-dose corticosteroids + IVIG + steroid-sparing agent (methotrexate/azathioprine): clinical remission in 40-60% of DM/PM; IVIG (ProQolity, FDA approved 2021 for DM): 79% response vs 44% placebo (PROPACK trial); rituximab in refractory: 77% response (RIM trial)
Gap size
Large for IBM (no effective treatment); moderate for DM/PM
Primary barrier
biological (IBM) + practice (DM/PM undertreated)
IBM (the most common myopathy in those >60 years) has no effective treatment despite multiple trial failures (bimagrumab, arimoclomol); DM/PM are managed with high-dose steroids first despite substantial side effects and emerging evidence for biologic first-line approaches
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Inflammatory Myopathies (Dermatomyositis / PM / IBM)” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."